title: Projecting future drug expenditures--1998.
abstract: Drug cost projections for 1998, factors that directly influence drug costs, and tools for projecting drug expenditures are discussed. The producer price index indicates that prices for drugs and pharmaceuticals increased 2.1% between January and June 1997; the increase for prescription preparations was 2.7%. Medi-Span data show an average increase for all drug products of 1.02% during the first six months of 1997; First Data-Bank reports a 1.7% increase for the same period. IMS America data, which take account of weighting for individual drugs or drug classes, show the prices of all drugs increasing 2.3% between the second quarters of 1996 and 1997. Drug industry analysts project the overall price increase in the next 12 months at 2-4%. Group purchasing organizations predict an average increase over the next 12 months of 0.56% for contracted drugs and 3.6% for noncontracted drugs. Various health care provider indexes suggest that increases in drug costs could be smaller over the next few years. The current trend of takeovers and mergers of pharmaceutical companies and health systems is likely to continue into 1998. As a result of generic competition and the loss of patent protection for many pharmaceutical products, the number of drugs to be introduced onto the market and the number of drugs in development are expected to escalate until the year 2000. These and other major changes in the health care environment, including changes in drug distribution and controversies over the use of formularies, will make future forecasting difficult. Compared with previous years, smaller increases in drug costs have been projected for 1998 and beyond, but changes in the health care environment mean that greater knowledge will be required to forecast future drug expenditures.
authors.affiliation: Department of Pharmacy, Mount Sinai Medical Center, New York, NY, USA.
authors.forename: B
authors.initials: B
authors.lastname: Mehl
authors.forename: J P
authors.initials: JP
authors.lastname: Santell
mesh_terms: D017277:Drug Approval; D016527:Drug Costs / Q000706:statistics & numerical data / Q000639:trends; D004345:Drug Industry / Q000191:economics; D011307:Drug Prescriptions / Q000191:economics; D004363:Drug Utilization / Q000191:economics* / Q000706:statistics & numerical data / Q000639:trends; D015507:Drugs, Investigational; D017850:Economics, Pharmaceutical / Q000706:statistics & numerical data / Q000639:trends*; D005569:Formularies as Topic; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D015507:Drugs, Investigational